Phase I evaluation of AT-125 single dose every three weeks.
A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D002490:Central Nervous System / Q000187:drug effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005973:Glutamine / Q000037:antagonists & inhibitors; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010080:Oxazoles / Q000009:adverse effects*
D000903:Antibiotics, Antineoplastic; D007555:Isoxazoles; D010080:Oxazoles; D005973:Glutamine; C006303:acivicin